CN115025042A - 一种吸入用硫酸沙丁胺醇溶液的制备方法 - Google Patents
一种吸入用硫酸沙丁胺醇溶液的制备方法 Download PDFInfo
- Publication number
- CN115025042A CN115025042A CN202210651978.9A CN202210651978A CN115025042A CN 115025042 A CN115025042 A CN 115025042A CN 202210651978 A CN202210651978 A CN 202210651978A CN 115025042 A CN115025042 A CN 115025042A
- Authority
- CN
- China
- Prior art keywords
- finished product
- salbutamol sulfate
- regulator
- preparation
- semi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 238000007789 sealing Methods 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims abstract description 9
- 239000011265 semifinished product Substances 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001301 oxygen Substances 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 238000007689 inspection Methods 0.000 claims abstract description 6
- 230000003204 osmotic effect Effects 0.000 claims abstract description 6
- 238000004806 packaging method and process Methods 0.000 claims abstract description 6
- 239000008215 water for injection Substances 0.000 claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 3
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 2
- 239000005388 borosilicate glass Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000004382 potting Methods 0.000 claims description 2
- 230000036512 infertility Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
本发明公开一种吸入用硫酸沙丁胺醇溶液的制备方法,包括:将渗透压调节剂和硫酸沙丁胺醇溶于注射用水中,然后用pH调节剂调节pH为3.3~3.8,经氮气除氧后药液经过滤除菌后进入灌封工序制得半成品,所述半成品经高压放电检漏、灯检后包装制得成品。该制备方法操作简易,工艺安全性好,无菌保障能力高,产品质量稳定,绿色环保无污染。
Description
技术领域
本发明属于医药技术领域,具体涉及一种吸入用硫酸沙丁胺醇溶液的制备方法。
背景技术
由于经济的快速发展和人口的迅速增多,全球性的大气污染问题已经逐渐的引起全世界人民的关注,大气污染所导致的呼吸系统疾病也是这些年一直讨论的话题。
沙丁胺醇作为选择性β2受体激动剂,能有效地抑制组胺等致过敏性物质的释放,防止支气管痉挛。适用于支气管哮喘、喘息性支气管炎、支气管痉挛、肺气肿等症。其在气管内吸收较慢,而且不易被体内的硫酸酶破坏,所以作用较强而持久,而且沙丁胺醇对心脏的β1受体的激动作用较弱,故其增加心率作用仅及异丙肾上腺素的1/10。
吸入用硫酸沙丁胺醇溶液在临床上与雾化器联动使用,可以将活性药物成分直接递送至肺部给药,解决了因口服药物服用后起效慢,生物利用度低的缺陷;所以对该产品要求无菌。
发明内容
经研究发现硫酸沙丁胺醇因其本身化学结构特性,在其制备和储存过程中对光、温度都敏感,随着光照和温度的持续,其质量会有明显下降,针对上述问题,本发明提供一种吸入用硫酸沙丁胺醇溶液的制备方法,该制备方法操作简易,工艺安全性好,无菌保障能力高,产品质量稳定,绿色环保无污染。
为实现上述目的,本发明采用如下的技术方案:
一种吸入用硫酸沙丁胺醇溶液的制备方法,包括:将渗透压调节剂和硫酸沙丁胺醇溶于注射用水中,然后用pH调节剂调节pH为3.3~3.8,经氮气除氧后药液经过滤除菌后进入灌封工序制得半成品,所述半成品经高压放电检漏、灯检后包装制得成品。
进一步的,所述渗透压调节剂为氯化钠,所述pH调节剂为硫酸。
进一步的,所述溶液中氯化钠含量为9mg/ml,沙丁胺醇含量为2mg/ml。
进一步的,硫酸沙丁胺醇溶解时控制温度在20±3℃。
进一步的,所述氮气的压力为0.1~0.3Mpa,所述的除氧的时间为60分钟。经除氧后氧含量小于0.3mg/L。
进一步的,所述的过滤为采用0.45um滤芯过滤后再经过两级0.22um除菌滤芯过滤。
进一步的,所述的灌封工序为:将除菌后的药液灌入经高温灭菌的棕色中硼硅玻璃安瓿中进行熔封。
本发明所采用的吸入用硫酸沙丁胺醇溶液的制备方法,该制备方法操作简易,工艺安全性好,无菌保障能力高,产品质量稳定,绿色环保无污染。
以价廉易得的氯化钠作为渗透压调节剂,硫酸作为pH调节剂,注射用水作为溶剂,通过简单的溶解、过滤及除菌过滤后灌装熔封,熔封后的半成品经高压放电检漏、灯检、包装得成品,整个工艺过程简单易操作,工艺安全性好,无菌保障能力高,产品质量稳定,绿色环保无污染。
具体实施方式
实施例1
在配液罐中加入600kg注射用水,然后加入6.75kg注射用氯化钠,开启搅拌,待固体全部溶解后将料液降温至20±3℃,然后加入1.8kg硫酸沙丁胺醇,继续搅拌溶清后加入药用级硫酸调节体系pH至3.5,调完后加入注射用水定容至750kg,然后通入氮气,调节氮气压力在0.1~0.3Mpa之间,通入60分钟除氧,检测氧含量小于0.3mg/L后将药液通过0.45um过滤器和两级0.22um除菌过滤器过滤后进行灌装熔封,熔封后的半成品高压放电检漏、灯检、包装得成品。
实施例2
在配液罐中加入300kg注射用水,然后加入3.375kg注射用氯化钠,开启搅拌,待固体全部溶解后将料液降温至20±3℃,然后加入0.9kg硫酸沙丁胺醇,继续搅拌溶清后加入药用级硫酸调节体系pH至3.4,调完后加入注射用水定容至375kg,然后通入氮气,调节氮气压力在0.1~0.3Mpa之间,通入60分钟除氧,检测氧含量小于0.3mg/L后将药液通过0.45um过滤器和两级0.22um除菌过滤器过滤后进行灌装熔封,熔封后的半成品高压放电检漏、灯检、包装得成品。
Claims (7)
1.一种吸入用硫酸沙丁胺醇溶液的制备方法,其特征在于,包括:将渗透压调节剂和硫酸沙丁胺醇溶于注射用水中,然后用pH调节剂调节pH为3.3~3.8,经氮气除氧后药液经过滤除菌后进入灌封工序制得半成品,所述半成品经高压放电检漏、灯检后包装制得成品。
2.根据权利要求1所述的制备方法,其特征在于,所述渗透压调节剂为氯化钠,所述pH调节剂为硫酸。
3.根据权利要求1所述的制备方法,其特征在于,所述溶液中氯化钠含量为9mg/ml,沙丁胺醇含量为2mg/ml。
4.根据权利要求1所述的制备方法,其特征在于,硫酸沙丁胺醇溶解时控制温度在20±3℃。
5.根据权利要求1所述的制备方法,其特征在于,所述氮气的压力为0.1~0.3Mpa,所述的除氧的时间为60分钟。
6.根据权利要求1所述的制备方法,其特征在于,所述的过滤为采用0.45um滤芯过滤后再经过两级0.22um除菌滤芯过滤。
7.根据权利要求1所述的制备方法,其特征在于,所述的灌封工序为:将除菌后的药液灌入经高温灭菌的棕色中硼硅玻璃安瓿中进行熔封。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210651978.9A CN115025042A (zh) | 2022-06-10 | 2022-06-10 | 一种吸入用硫酸沙丁胺醇溶液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210651978.9A CN115025042A (zh) | 2022-06-10 | 2022-06-10 | 一种吸入用硫酸沙丁胺醇溶液的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115025042A true CN115025042A (zh) | 2022-09-09 |
Family
ID=83123789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210651978.9A Pending CN115025042A (zh) | 2022-06-10 | 2022-06-10 | 一种吸入用硫酸沙丁胺醇溶液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115025042A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107126416A (zh) * | 2016-02-26 | 2017-09-05 | 上海信谊金朱药业有限公司 | 硫酸沙丁胺醇雾化吸入溶液的制备方法 |
CN112402400A (zh) * | 2019-08-22 | 2021-02-26 | 上海上药信谊药厂有限公司 | 硫酸沙丁胺醇雾化吸入溶液及其制备工艺和应用 |
CN113476428A (zh) * | 2021-01-28 | 2021-10-08 | 朗天药业(湖北)有限公司 | 一种吸入用硫酸沙丁胺醇溶液及其制备方法 |
-
2022
- 2022-06-10 CN CN202210651978.9A patent/CN115025042A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107126416A (zh) * | 2016-02-26 | 2017-09-05 | 上海信谊金朱药业有限公司 | 硫酸沙丁胺醇雾化吸入溶液的制备方法 |
CN112402400A (zh) * | 2019-08-22 | 2021-02-26 | 上海上药信谊药厂有限公司 | 硫酸沙丁胺醇雾化吸入溶液及其制备工艺和应用 |
CN113476428A (zh) * | 2021-01-28 | 2021-10-08 | 朗天药业(湖北)有限公司 | 一种吸入用硫酸沙丁胺醇溶液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112891300B (zh) | 一种盐酸氨溴索注射液及其制备方法 | |
JP2006291028A (ja) | 低分子ヘパリンまたはその塩、ならびにその製造方法 | |
CN111840259B (zh) | 一种间苯三酚和三甲基间苯三酚的注射液及其制备方法 | |
CN112245412B (zh) | 一种吸入用乙酰半胱氨酸溶液及其制备方法与应用 | |
CN115025042A (zh) | 一种吸入用硫酸沙丁胺醇溶液的制备方法 | |
CN112168782A (zh) | 一种呼吸系统药物口服喷雾剂的制备方法 | |
CN114288385B (zh) | 一种醋酸奥曲肽制剂的制备方法 | |
CN110200905B (zh) | 一种盐酸氨溴索组合物及其注射液与应用 | |
CN109806223A (zh) | 一种碳酸氢钠注射液的生产方法 | |
CN112168776B (zh) | 一种低杂质高稳定的托拉塞米注射液和制备方法 | |
CN104434788B (zh) | 一种阿替洛尔注射液的制备方法 | |
CN115869255B (zh) | 一种呋塞米注射液的组成及制备方法 | |
CN114917207A (zh) | 一种硫酸特布他林雾化吸入用溶液的制备方法 | |
CN113230207A (zh) | 一种葡萄糖酸钙氯化钠注射液的制备工艺 | |
CN100998585A (zh) | 一种盐酸甲氯芬酯注射液的制剂及其制备方法 | |
CN112321751A (zh) | 一种高品质依诺肝素钠的精制方法 | |
CN116350581B (zh) | 一种乙酰半胱氨酸注射液的制备方法 | |
CN104840417A (zh) | 一种盐酸氨溴索注射液及其制备方法 | |
CN109381459B (zh) | 一种含10种氨基酸的药物组合物及其制备方法 | |
JP2006525240A5 (zh) | ||
CN115887364A (zh) | 一种盐酸林可霉素注射液及其制备方法 | |
CN116440158B (zh) | 一种蔗糖铁组合物、其制备方法及应用 | |
CN107982303B (zh) | 大株红景天注射液的醇沉方法 | |
CN105796484A (zh) | 一种炎琥宁注射液及其制备方法 | |
CN107320445B (zh) | 一种盐酸氨溴索注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220909 |